+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale



The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale



Bmc Nephrology 18(1): 117



Iron deficiency anemia (IDA) is a common manifestation of chronic kidney disease (CKD), affecting most patients on hemodialysis and imposing a substantial clinical burden. Treatment with iron supplementation increases hemoglobin levels and can reduce the severity of anemia in patients with CKD. While correcting anemia in these patients is an important therapeutic goal, there is a lack of long-term trials directly comparing intravenous iron therapies in patients with CKD receiving hemodialysis. The Ferumoxytol for Anemia of CKD Trial (FACT) is a 13-month, open-label, randomized, multicenter, international, prospective study with 2 substudies. Entry criteria for the main study include adults with IDA (defined as hemoglobin <11.5 g/dL [<115.0 g/L] and a transferrin saturation <30%), serum ferritin <800 ng/mL (<1798 pmol/L), and receiving hemodialysis for ≥3 months. Patients are randomized to receive ferumoxytol (1.02 g over 2 doses) or iron sucrose (1.0 g over 10 doses) during the initial 5-week treatment period. Those with persistent/recurrent IDA over the 11-month observation period will receive additional 5-week treatment periods, as appropriate. The primary efficacy endpoint of the main study is the mean change in hemoglobin from Baseline to Week 5 for each treatment period. The secondary efficacy endpoints include the mean change in transferrin saturation from Baseline to Week 5 and the proportion of patients with a hemoglobin increase of ≥1.0 g/dL at any time from Baseline to Week 5. Safety will be assessed through an examination of the adverse event profile over the course of the study. An "oxidative stress" substudy in approximately 100 patients will assess the effects of treatment on biomarkers of oxidative stress/inflammation during the initial 5-week treatment period, and a magnetic resonance imaging substudy in approximately 70 patients will assess the potential for iron deposition in target tissues over 24 months. FACT fulfills the need for a long-term comparative trial in patients with IDA and CKD receiving hemodialysis. The efficacy and safety results will provide useful information for guiding therapy in this population. Two hundred ninety-six patients have been enrolled, and completion of the main study is expected soon. ClinicalTrials.gov identifier: NCT01227616 (registered October 22, 2010); EudraCT number: 2010-022133-28.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060350353

Download citation: RISBibTeXText

PMID: 28372549

DOI: 10.1186/s12882-017-0523-8


Related references

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
. Clinical Nephrology 91(4): 237-245, 2019

A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology 89(6): 646-650, 2014

Tu1743 Iv Iron Treatment of Iron Deficiency Anemia with Ferumoxytol in Patients with Inflammatory Bowel Disease Unable to Take Oral Iron: A Randomized Controlled Trial Versus Ferric Carboxymaltose. Gastroenterology 156(6): S-1107-S-1108, 2019

Tu1073 Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients With Gastrointestinal Disorders Who Have a History of Unsatisfactory Oral Iron Therapy: Results of a Phase Iii, Randomized, Placebo-Controlled Trial. Gastroenterology 144(5): S-754, 2013

Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. Bmc Hematology 16: 20, 2016

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clinical Journal of the American Society of Nephrology 9(4): 705-712, 2014

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. American Journal of Hematology 93(5): 683-690, 2018

The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrology Dialysis Transplantation 29(4): 843-850, 2014

Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. Journal of Blood Medicine 8: 155-163, 2017

Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clinical Journal of the American Society of Nephrology 1(3): 475-482, 2006

Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. Nephron 143(2): 77-85, 2019

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clinical Journal of the American Society of Nephrology 4(2): 386-393, 2009

Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 133(1): 43-48, 2016

Intravenous Ferumoxytol in Pediatric Patients With Iron Deficiency Anemia. Annals of PharmacoTherapy 51(7): 548-554, 2017

Treatment of iron-deficiency anemia with IV ferumoxytol in CKD patients: Efficacy compared with oral iron across different age groups. 2007